stockrow
Saturday 7 November 2026
Export ZBIO’s income statement to Excel — free account
Zenas BioPharma, Inc.
ZBIO Healthcare Biotechnology
Zenas BioPharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.0 million, up 100.0% from fiscal 2024.
- EPS
- −35.3%
- Free cash flow
- −41.0%
Quarter to September 2026, against a year earlier
28.26
2.33
+8.99%
Follow ZBIO
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | — |
+8 more quarters Free account |
P/S ratio |
25.13 | 0.00 | — | — | |
P/FCF ratio |
0.00 | 0.00 | — | — | |
P/Operating CF |
(30.77) | (27.99) | — | — | |
P/B ratio |
8.40 | 6.48 | — | — | |
Price to Tangible BV |
8.40 | 6.48 | — | — | |
EV/Sales |
22.36 | 0.00 | — | — | |
EV/EBITDA |
0.00 | 0.00 | — | — | |
EV/Operating CF |
(6.54) | (5.96) | — | — | |
EV/FCF |
(6.54) | (5.96) | — | — | |
Quick Ratio |
9.14 | 9.77 | 11.73 | 5.48 | |
Current Ratio |
9.42 | 9.93 | 11.94 | 5.61 | |
Net Debt/EBITDA |
5.66 | 2.36 | 4.74 | 1.11 | |
Debt/Assets |
0.00% | 55.40% | 46.89% | 20.50% | |
Debt/Equity |
0.00 | 1.57 | 1.04 | 0.32 | |
Asset Turnover |
0.14 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.53 | 0.51 | 0.93 | 0.22 | |
Capex/Depreciation |
(0.25) | 0.00 | (0.33) | 0.00 | |
Interest Coverage |
— | (10.45) | (11.66) | — | |
Research and Development Expense of Revenue |
584.74% | 6,291.30% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
274.35% | 1,574.60% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
172.76% | 861.90% | 0.00% | 0.00% | |
Graham Net Nets |
0.08 | 0.12 | — | — | |
Graham Number |
0.00 | 0.00 | — | — | |
Earnings Yield |
(34.93%) | (35.42%) | — | — | |
Free Cash Flow Yield |
(13.61%) | (14.11%) | — | — | |
Revenue per Share |
0.15 | 0.02 | 0.00 | 0.00 | |
Operating CF per Share |
(0.88) | (0.91) | (1.35) | (1.17) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.88) | (0.91) | (1.35) | (1.17) | |
Cash per Share |
8.85 | 10.19 | 12.89 | 7.67 | |
Shareholders Equity per Share |
3.21 | 3.92 | 6.04 | 5.41 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.21 | 3.92 | 6.04 | 5.41 | |
Free Cash Flow |
(57.98) | (57.24) | (75.20) | (52.41) | |
Working Capital |
539.41 | 587.98 | 669.00 | 288.52 | |
Capital Expenditures |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Current Asset Value |
140.54 | 199.20 | 318.31 | 209.68 | |
EV/EBIT |
0.00 | 0.00 | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Payables |
6.75 | 7.76 | 14.48 | 12.12 | |
Average Assets |
498.62 | 497.39 | 540.72 | 376.80 | |
Average Common Equity |
204.37 | 243.36 | 310.07 | 277.30 |
Columns are period end dates · fundamentals updated 5 Nov 2026